Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.
|Articles|June 9, 2009
- Summer 2009
- Volume 8
- Issue 2
Hair Loss Snapshot
Author(s)Lacey Meyer
A list of drugs and their effects on hair loss.
Advertisement
>
Adriamycin (doxorubicin)
>
Camptosar (irinotecan)
>
Cytoxan (cyclophosphamide)
>
Ellence (epirubicin)
>
Taxol (paclitaxel)
>
Taxotere (docetaxel)
>
Erbitux (cetuximab)
>
Faslodex (fulvestrant)
>
Gemzar (gemcitabine)
>
Gleevec (imatinib)
>
Herceptin (trastuzumab)
>
Sutent (sunitinib)
>
Tamoxifen
>
Tarceva (erlotinib)
>
Tykerb (lapatinib)
>
Xeloda (capecitabine)
Articles in this issue
about 17 years ago
Web Exclusive: Find a Clinical Trial That's Right for Youabout 17 years ago
Web Exclusive: Find a Clinical Trial That's Right for Youover 17 years ago
Web Exclusive: A Q&A with an Extraordinary Healerover 17 years ago
Web Exclusive: Types of Kidney Cancerover 17 years ago
Web Exclusive: Helpful Adviceover 17 years ago
Web Exclusive: Developing a Strategyover 17 years ago
Web Exclusive: Searching for New Targetsover 17 years ago
Web Exclusive: When Survivors Should Exercise Cautionover 17 years ago
Web Exclusive: Fertility Guidelines Not Meeting Needs of Patientsover 17 years ago
Web Exclusive: A Peaceful SpiritAdvertisement
Related to this article
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Dr. Nitin Ohri explains how radiation treats cancer, how often treatment is needed, common side effects and how to tell if radiation is working.
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
Advertisement
Advertisement
Trending on CURE
1
Hot Flashes From Breast Cancer Treatment May Soon Have an FDA-Approved Fix
2
The 5 Most Impactful Phase 3 Cancer Trial Results From September 2026
3
10 Cancer Treatment Approvals From September 2026 and What They Mean for You
4
Shorter Radiation After Prostate Surgery Controlled Cancer as Well at 5 Years, With a Trade-Off
5